Markers such as MDA and MPO, which have demonstrated prognostic value and are implicated in oxidative stress–induced cardiomyopathy [55], may serve as actionable targets to evaluate and enhance the impact of interventions aimed at reducing oxidative stress and inflammation. The gene discussed is MPO; the disease is cardiomyopathy.